Targeting drug-resistant mutations in ALK.

doi:10.1038/s43018-022-00390-1

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Targeting drug-resistant mutations in ALK.

Nature cancer - 1 Jun 2022

He Liu, Dar Arvin C

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Carcinoma, Non-Small-Cell Lung
Share to Lung Neoplasms
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 35726064
DOI: 10.1038/s43018-022-00390-1
PMCID: PMC9919885

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting drug-resistant mutations in ALK.PMID 35726064Read ↗

[Molecular targeted drugs against ALK fusions].Semantic proximity Read ↗

Targeting ALK: Precision Medicine Takes on Drug Resistance.Semantic proximity Read ↗

Resistance to ALK inhibitors: Pharmacokinetics, mutations or bypass signaling?Semantic proximity Read ↗

New perspectives for targeting therapy in ALK-positive human cancersSemantic proximity Read ↗

EML4-ALK: Update on ALK InhibitorsSemantic proximity Read ↗

ALK gene alterations in cancer: biological aspects and therapeutic implications.Semantic proximity Read ↗

Drug resistance in ALK-positiveNon-small cell lungcancer patientsSemantic proximity Read ↗

Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenarioSemantic proximity Read ↗

Targeting oncogenic ALK: a promising strategy for cancer treatment.Semantic proximity Read ↗

Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors.Semantic proximity Read ↗

A Pan-Cancer Review of ALK Mutations: Implications for Carcinogenesis and Therapy.Semantic proximity Read ↗

Managing Resistance to EFGR- and ALK-Targeted Therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.